Learn How to Incorporate Lynda.com Into Your Curriculum
UC students, faculty and staff can access Lynda.com (a LinkedIn company) anytime, anywhere to enhance technology and professional skills. The site features over 5,000 courses on topics such as Microsoft Office, business skills, IT skills and much more. With constantly growing content, updated weekly, Lynda offers the training necessary to stay ahead of the curve.
If all this good news is overwhelming, no worries. Weve got your back. Come and learn from Laurie Burruss on all the different ways this tool can be used to supplement your work.
Laurie is a professor emeritus at Pasadena City College and a consultant in education at Lynda.com where shes advocated for academic initiatives, supported teaching and learning, and provided integration and implementation solutions since 2009. Laurie will also be meeting with student groups to discuss how to best utilize courses in professional development and courses to assist and prepare them for current UC classes.
Sessions will be offered on March 31:
- All-campus session (faculty focused): 9:30 a.m.-11 a.m. in 400C TUC
- UCAAMP session: 1:00-2:00 p.m. UCAAMP members register here.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.